Literature DB >> 23280871

Prevention of diabetes: a strategic approach for individual patients.

Jeong-Ah Shin1, Jin-Hee Lee, Hun-Sung Kim, Yoon-Hee Choi, Jae-Hyoung Cho, Kun-Ho Yoon.   

Abstract

The 'diabetes epidemic' is an important health and socioeconomic problem worldwide. Type 2 diabetes is a chronic disease with gradual deterioration in glucose metabolism which causes multiple systemic complications. Therefore, early intervention in the prediabetic stage is a valuable approach to reduce diabetes development and related complications. Many clinical trials have suggested that lifestyle intervention, including moderate-intensity exercise and diet control, and pharmacologic intervention using metformin, α-glucosidase inhibitors, thiazolidinediones, anti-obesity drugs and incretin mimics, are effective in preventing diabetes development. However, an individualized approach with careful consideration of the patient's risk status and health economics is needed to perform a successful intervention programmes. In this review, we will summarize the known evidence on treatment- and cost-effectiveness of drug and lifestyle treatment. Additionally, we will propose a strategic approach algorithm that is applicable to clinical practice.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280871     DOI: 10.1002/dmrr.2357

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

1.  Guideline approach to therapy in patients with newly diagnosed type 2 diabetes.

Authors:  Itamar Raz
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

2.  The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program.

Authors:  Anne Neumann; Lars Lindholm; Margareta Norberg; Olaf Schoffer; Stefanie J Klug; Fredrik Norström
Journal:  Eur J Health Econ       Date:  2016-12-02

3.  Lifestyle Modifies the Diabetes-Related Metabolic Risk, Conditional on Individual Genetic Differences.

Authors:  Jisu Shin; Xuan Zhou; Joanne T M Tan; Elina Hyppönen; Beben Benyamin; S Hong Lee
Journal:  Front Genet       Date:  2022-03-09       Impact factor: 4.599

4.  The Inhibitory Effects of New Zealand Pine Bark (Enzogenol®) on α-Amylase, α-Glucosidase, and Dipeptidyl Peptidase-4 (DPP-4) Enzymes.

Authors:  Wen Xin Janice Lim; Cheryl S Gammon; Pamela von Hurst; Lynne Chepulis; Rachel A Page
Journal:  Nutrients       Date:  2022-04-12       Impact factor: 6.706

5.  Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa.

Authors:  Asman Manaf; Raymond R Tjandrawinata; Desi Malinda
Journal:  Drug Des Devel Ther       Date:  2016-03-29       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.